LGC says entry into bioanalytical services space through the acquisition of Quotient testing division is part of a wider expansion plan.
The UK firm acquired the Quotient business last week, explaining that the move into bioanalytical analysis rounds out its existing materials science and reference materials services offering.
LGC spokesman Julian Quigley told in-Pharmatechnologist.com that: “Quotient’s bioanalysis, biomarkers and microbiology services fit very well within LGC,” adding that the unit’s lab in Fordham, Cambridgeshire and 160-strong workforce “all transfer to LGC as part of the deal.”
He added that the acquired unit will continue to operate as Quotient for the "time being" and LCG will continue to work with existing customers to support ongoing clinical trials and radiolabelling projects as a 'preferred partner.'
The deal – financial terms of which were not disclosed – follows just weeks after a number of others LGC has made in its pharmaceutical services business.
In December, for example, the firm acquired microbiology testing company Bio Senate, which provides a range of analytical services to the pharmaceutical, food and water industries.
A month before that LGC opened its genomics testing laboratory in Hoddesdon increasing its capacity to produce research reagents for academia and the pharmaceutical development sector.
The latest deal also follows two years after LGC bought Quotient’s sports doping detection business, HFL Sport Science, which operates testing labs that are based at the Fordham facility.